AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval

AbbVie is looking to file for accelerated approval of telisotuzumab vedotin (Teliso-V) after reporting positive topline Phase II results for its investigational c-Met protein directed antibody-drug conjugate, which showed a “compelling” overall response rate in patients with previously treated non-small cell lung cancer.